NewLink Genetics Receives $43,400,000 New Funding Round

  • Feed Type
  • Date
    11/11/2011
  • Company Name
    NewLink Genetics
  • Mailing Address
    2503 South Loop Drive Ames, IN 50010
  • Company Description
    NewLink Genetics (NASDAQ: NLNK) is an emerging biopharmaceutical company focused on discovery and development of novel, immunotherapeutic agents. Our mission is to achieve breakthrough improvements in the survival and quality-of-life of cancer patients. The company has advanced two product platforms into human clinical trials. Its HyperAcute therapeutic vaccines for treatment of pancreatic cancer and lung cancer are progressing in Phase II efficacy studies, and NewLink’s first-in-class, small-molecule inhibitor of the IDO* pathway is undergoing Phase I testing for safety.
  • Website
    http://www.newlinkgenetics.com
  • Transaction Type
    IPO
  • Transaction Amount
    $43,400,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

Trending on Xconomy